In the early 19th century, the French physician Pierre-Charles-Alexandre Louis did something medicine had rarely done before: he counted.
At the time, bloodletting was standard. It was elegant, logical, and universally accepted. If an imbalance of humors caused disease, removing blood should fix it. The theory made sense. The practice was everywhere.
Louis compared outcomes among patients with pneumonia who were bled early and aggressively to those who were not, and found that bloodletting didn’t help.
If anything, it made things worse.
That single act—placing belief next to data—began to unravel one of medicine’s most entrenched practices, forcing doctors to confront a dangerous possibility: a treatment can be coherent, widely accepted, and completely wrong.
Now, imagine if the medical establishment had ignored that finding, and doubled down—expanding bloodletting to younger and healthier people.
That is where we are with cholesterol.
In March of last year, the New England Journal of Medicine published a paper that should have ignited a revolution. Spanning millions of participants, hundreds of cohorts, and decades of follow-up, it is the largest and most comprehensive study ever performed on cardiovascular risk factors.
If the Lipid Hypothesis—the idea that elevated cholesterol is the primary cause of heart disease—were true, this study should have cemented it.
But it didn’t.
Every other classic risk factor behaved as expected, showing a robust statistical association with heart disease and death: Smoking. High blood pressure. Diabetes. Obesity.
But not high cholesterol.
Hyperlipidemia, as defined by the AHA, was the only ‘risk factor’ whose point estimates drifted to the wrong side of the ledger. Numerically, it was associated with longer life and less heart disease.
That finding, the clearest demonstration that hyperlipidemia as defined by the AHA is not, and never was, an important risk factor for heart disease, should have triggered a reckoning in medicine.
Instead, it was ignored. The new AHA guideline—134 pages devoted to identifying and treating cardiovascular risk—does not mention, cite, or even acknowledge the most important study ever published on cardiovascular risk.
But the study’s findings didn’t come out of nowhere.
In 2011, a JAMA study of more than 500,000 patients with a first-ever heart attack found that just 28% had hyperlipidemia. In other words, nearly three quarters of people having their first heart attack did not have the condition the AHA says causes first heart attacks.
Think about that.
It gets worse: Among healthy adults, roughly half meet the AHA’s definition of hyperlipidemia. Yet the 2011 study found that among people having a heart attack, hyperlipidemia is present in barely a quarter.
That made high cholesterol unique among the study’s risk factors, because it was more common among people without heart problems than people having heart attacks.
Is that a risk factor? Um, no.
A risk factor is supposed to be more common among those headed toward the disease than among those who are not. Hyperlipidemia failed that test years ago.
Meanwhile, lipid-lowering therapy has expanded relentlessly for decades. Statins became ubiquitous. Newer drugs drive LDL levels to previously unthinkable lows.
If cholesterol were the central driver of heart disease, we should therefore be witnessing the disappearance of heart disease.
We are not.
Heart disease mortality was falling precipitously well before the advent of statins, a decline that slowed once the drugs became ubiquitous. And now, with cholesterol levels lower than ever, the decline has disappeared—the curve hasflattened.
The AHA’s latest guideline, however, doubles down—recommending cholesterol screening and treatment not just for people like those in trials of the drugs, who already had heart disease or were at ultra-high risk. But for teenagers and children—heart healthy youths, decades from any possibility of heart disease.
The AHA then parades their self-delusion, classifying this as a ‘IA’ recommendation, a designation to indicate their strongest possible recommendation (‘I’) , ostensibly based on multiple randomized trials (‘A’). But no trial has ever shown a benefit for testing, much less treating, cholesterol in children.
Thus the AHA brazenly disregards even its own classification system, in order to promote the treatment of lipids.
Breathtaking.
They could have gone in a different direction. Acknowledging the failure of the Lipid Hypothesis would not require conceding that cholesterol is irrelevant. Extreme abnormalities matter. Treating lipids in high-risk or secondary prevention populations can still be reasonable and helpful.
But a risk factor for heart disease that fails to be a risk factor in the best study ever done, and that’s more common in healthy people than those having heart attacks—cannot credibly be called the central cause of heart disease.
Yet that is exactly the AHA’s theory, and the silent infrastructure for the guideline.
The AHA has become something different from what it claims to be: not a scientific body responding to evidence, but a signaling institution—translating a dumbed-down, cholesterol-centric theory into screening programs, drug pathways, and public messaging.
And once a theory becomes infrastructure—once it supports careers, industries, and the identity of an institution—it stops being something you test.
It becomes something you protect. At all costs.
The sad fact is that medicine didn’t abandon bloodletting by arguing about it. They abandoned it when continuing to defend it became embarrassing.
Cholesterol has quietly reached that point. But the AHA, with guideline committees living in a bubble that protects them from scientific fact, doesn’t know it.
Or worse—they do, and they’ve decided it’s still better to keep bleeding us all.
